Faron Pharmaceuticals Oy (FRA:4FR) GF Score: 21/100 (As of Jul. 07, 2026) — 38% Below Median


FRA:4FR Faron Pharmaceuticals Oy FRA:4FR
21 GF Score
Price €0.51
! 4 Warning Signs
View Full Analysis

What is Faron Pharmaceuticals Oy GF Score?

Faron Pharmaceuticals Oy FRA:4FR -1.37% 21 GF Score is 21 as of Jul. 07, 2026, which is 38% below its 10-year median of 34.00. GuruFocus rates FRA:4FR with a GF Score™ of 21/100. The stock has 4 warning signs investors should review.

Faron Pharmaceuticals Oy has the GF Score of 21, which implies that the company might have Worst future performance potential, or not enough data.

The GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation, which has been found to be closely correlated to the long-term performances of stocks by backtesting from 2006 to 2021. The stocks with a higher GF Score generally generate higher returns than those with lower GF Scores. Therefore, when picking stocks, investors should invest in companies with high GF Scores. The GF Score ranges from 0 to 100, with 100 as the highest rank.

GF Score takes following five key aspects into consideration:

1. Financial Strength : 5/10
2. Profitability Rank : 0/10
3. Growth Rank : 0/10
4. GF Value Rank : 0/10
5. Momentum Rank : 2/10

Each one of these components is ranked and the ranks also have positive correlation with the long term performances of stocks. The GF score is calculated using the five key aspects of analysis. Through backtesting, we know that each of these key aspects has a different impact on the stock price performance. Thus, they are weighted differently when calculating the total score. The Profitability Rank and the Growth Rank are weighted fully, while other parameters have less weight.

Based on research and backtesting result, GuruFocus believes Faron Pharmaceuticals Oy might have Worst future performance potential, or not enough data.

Please click GF Score to see more details on the GF Score's 5 Key Aspects of Analysis.

Faron Pharmaceuticals Oy  (FRA:4FR) GF Score Explanation

Based on the historical long-term performances among five valuation aspects, the GF Score is found to be closely correlated to the long-term performances of stocks. It ranges from 0 to 100, with 100 as the highest. GuruFocus divided GF Score into following 5 categories:

GF Score Performance Potential and All-in-One Screener Examples (1)
91 - 100Highest outperformance potential
81 - 90Good outperformance potential
71 - 80Likely to have average performance
51 - 70Poor future performance potential
0 - 50Worst future performance potential, or not enough data

(1) These are some simple examples. You can access our GF Score filter under All-in-One Screener’s Fundamental tab.

Faron Pharmaceuticals Oy GF Score Related Terms

FRA:4FR vs VRTX, REGN, ALNY: GF Score Comparison

For the Biotechnology subindustry, Faron Pharmaceuticals Oy's GF Score, along with its competitors' market caps and GF Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Faron Pharmaceuticals Oy GF Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Faron Pharmaceuticals Oy's GF Score distribution charts can be found below:

* The bar in red indicates where Faron Pharmaceuticals Oy's GF Score falls into.


FRA:4FR
21GF Score
Faron Pharmaceuticals Oy FRA:4FR
GF Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about GF Score →
What does a GF Score of 21 mean?
Faron Pharmaceuticals Oy (FRA:4FR) has a GF Score of 21 as of Jul. 07, 2026. GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation. View historical data on Faron Pharmaceuticals Oy and its competitors. This is 38% below median its historical median of 34.00. Over the past decade, Faron Pharmaceuticals Oy's GF Score has ranged from 16.00 to 39.00.
Is Faron Pharmaceuticals Oy's GF Score too high?
Faron Pharmaceuticals Oy's current GF Score of 21 is 38% below median its 10-year median of 34.00. Over the past 10 years, this metric has ranged from a low of 16.00 to a high of 39.00. Overall, Faron Pharmaceuticals Oy has a GF Score™ of 21/100, reflecting its overall financial health beyond just this single metric.
How does Faron Pharmaceuticals Oy's GF Score compare to VRTX and REGN?
Faron Pharmaceuticals Oy's GF Score of 21 can be compared against companies in the Biotechnology industry. Historically, Faron Pharmaceuticals Oy's own GF Score has ranged from 16.00 to 39.00 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good GF Score for a Biotechnology company?
A good GF Score depends on the Biotechnology industry context. However, GF Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high GF Score mean?
A high GF Score can signal that a stock is expensive relative to its fundamentals. GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation. View historical data on Faron Pharmaceuticals Oy and its competitors. Faron Pharmaceuticals Oy's current GF Score is 21, which is 38% below median its own 10-year median of 34.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Faron Pharmaceuticals Oy stock overvalued right now?
Faron Pharmaceuticals Oy (FRA:4FR) has a current GF Score of 21. The current GF Score is 21, which is 38% below median its 10-year median of 34.00. Faron Pharmaceuticals Oy's overall GF Score™ is 21/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is GF Score calculated?
GF Score is calculated from a company's financial statements. For Faron Pharmaceuticals Oy (FRA:4FR), the current GF Score is 21 as of Jul. 07, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Faron Pharmaceuticals Oy Business Description

Other Exchanges FARN:UKFARON:Finland
Address Joukahaisenkatu 6 B, Turku, FIN, 20520
Faron Pharmaceuticals Oy is a clinical-stage biopharmaceutical company. The company has one operating and reportable segment. The Group has a pipeline based on the receptors involved in the regulation of immune response in oncology, organ damage, and bone marrow regeneration. Faron is a late clinical stage drug discovery and development Group. The company includes Bexmarilimab in its pipeline. Bexmarilimab is Faron's wholly owned, investigational immunotherapy designed to overcome resistance to existing treatments and improve clinical outcomes by targeting myeloid cell function in the microenvironment and igniting the immune system against cancer.
21GF Score

Get the complete analysis for FRA:4FR

GF Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.51
Price